Advent Life Sciences
VC Fund
London, United Kingdom
Advent Life Sciences is a venture team investing in life sciences businesses. The team consists of 11 professionals with extensive scientific, medical and operational experience, and a long-standing track record of entrepreneurial and investment success across the UK, Europe and the US. The Firm invests in a range of sectors within life sciences,principally in new drug discovery, enabling technologies, and med tech. Realizations in the last three years include Algeta, Avila, CN Creative, EUSA, Micromet. Current investments include Acutus, Biocartis, Cellnovo, f2G, NeRRe,
- Total investments:
- 71
- Last investment:
- Lead investor:
- 35%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Advent Life Sciences invests in
Stages Advent Life Sciences invests in
Countries Advent Life Sciences invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $5.5M–$51M
- Series B
- $21M–$97M
Investment Focus
Industry
- Biotechnology 32 (45%)
- Health Care 22 (31%)
- Medical 13 (18%)
- Therapeutics 10 (14%)
- Pharmaceutical 10 (14%)
Stage
- Series A 17 (24%)
- Series B 14 (20%)
- Funding Round 9 (13%)
- Series C 8 (11%)
- Venture - Series Unknown 5 (7%)
Country
- United States 18 (25%)
- United Kingdom 17 (24%)
- France 2 (3%)
- Spain 1 (1%)
- Norway 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andrew J Wood
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Dale Pfost
General Partner
|
General Partner | Total investments: 2 | Find email | |
Kaasim Mahmood
General Partner
|
General Partner | Total investments: 2 | Find email | |
Satish Jindal
General Partner
|
General Partner | Total investments: 2 | Find email | |
Shahzad Malik
General Partner
|
General Partner | Total investments: 17 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cyted
|
Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use artificial intelligence and novel biomarkers to unlock clinical insight and improve patient outcomes. Cyted's mission is to revolutionise diagnostic methods to build a world where disease is prevented rather thantreated. | $44M / Series B / Aug 30, 2025 | |
Glycomine
|
Glycomine is early-stage biotech working on replacement therapies for rare diseases. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA-approved treatment. Glycomine develops therapeutics for diseases that have no treatment options. | $115M / Series C / Apr 16, 2025 | |
Relief Cardiovascular
|
Relief Cardiovascular is an inQB8 medical technologies portfolio company developing a revolutionary smart implant to decongest heart failure patients. | $12M / Series A / Jan 08, 2025 | |
Epitopea
|
Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, andbioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal. | $31M / Seed / Oct 24, 2024 | |
|
Epitopea
|
Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, andbioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal. | $31M / Seed / Oct 24, 2024 | |
Moximed
|
Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis. | $61M / Series D / Aug 13, 2024 | |
Artax Biopharma
|
Artax Biopharma is a development-stage biopharmaceutical company that is dedicated to the development of new therapies for autoimmune and inflammatory diseases. Its technology provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.The companywas founded in 2013 and is headquartered in Cambridge, Massachusetts. | $8M / Convertible Note / Aug 06, 2024 | |
Beacon Therapeutics
|
Beacon Therapeutics is an ophthalmic gene therapy company that restores and improves vision and rare retinal diseases that result in blindness. | $170M / Series B / Jun 03, 2024 | |
Curve Therapeutics
|
Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs. | $51.4M / Series A / Feb 27, 2024 | |
Arga Medtech
|
Argá Medtech is an Innovative Cardiac Ablation System for treating cardiac arrhythmias. | $58.5M / Series B / Feb 27, 2024 | |
| See all 71 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Advent Life Sciences invest in?
Advent Life Sciences invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 71 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Advent Life Sciences's check size?
Advent Life Sciences typically joins rounds of $5.5M–$51M at Series A and $21M–$97M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Advent Life Sciences participates in.
How do I contact Advent Life Sciences?
Public channels for Advent Life Sciences include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Advent Life Sciences?
The team at Advent Life Sciences includes Andrew J Wood (Venture Partner), Dale Pfost (General Partner) and Kaasim Mahmood (General Partner), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
